Benign Prostatic Hyperplasia and Kidney Stone Disease Thermobalancing Therapy with Dr Allen’s Device: Key to Successful Ageing Without Medications, Surgery, and Risky Exposure to Coronavirus Infection

Background: The choice of treatment for benign prostatic hyperplasia (BPH) and kidney stone disease (KSD) impacts the attainment of successful ageing and the level of patient care required in the long-term. Medications and surgeries typically used for these conditions have serious side effects and can interfere with healthy aging. Objectives: This study assesses the impact of Dr Allen’s Therapeutic devices (DATD) and thermobalancing therapy® (TT) on the ageing process of people with BPH and KSD. Methods: This study evaluated the outcomes of a clinical trial investigating the dynamics of symptoms and parameters in 124 male patients with BPH who used DATD as a monotherapy for six months at home and compared the results with a control group including 124 BPH patients who did not receive treatment with DATD. Furthermore, five case studies were randomly selected for assessment from 10-year empirical observations of patients with KSD treated with DATD. Results: DATD with TT reduced prostate volume (PV) from 45 mL to 31 mL (P < 0.001) and reduced urinary symptoms score from 14.2 to 4.9 (P < 0.001). It also improved quality of life (QoL) as measured by the reduction in the International Prostate Symptom score (I-PSS) from 3.9 to 1.3 (P < 0.001), while the control group showed no positive changes. DATD with TT dissolved kidney stones without renal colic in all patients. No side effects were observed. Conclusions: Using DATD and TT to treat BPH and KSD demonstrated high efficacy, safety, and easy disease management at home. In contrast, medications and surgeries for BPH and KSD often lead to sexual dysfunction, depression, hypertension, chronic kidney failure, and other morbidities, requiring an increased care level in the long-term. Thus, DATD and TT generate high treatment efficacy with lower exposure to coronavirus, reduce long-term care needs, and are vital to attaining successful ageing and longevity.

Download Full-text

Treatment of Kidney Stone Disease, Benign Prostatic Hyperplasia and Chronic Prostatitis with Thermobalancing Therapy should be listed in the Guidance for Health Professionals

ARC Journal of Urology ◽

10.20431/2456-060x.0302001 ◽

2018 ◽

Vol 3 (2) ◽

Keyword(s):

Benign Prostatic Hyperplasia ◽

Health Professionals ◽

Kidney Stone ◽

Chronic Prostatitis ◽

Stone Disease ◽

Prostatic Hyperplasia ◽

Kidney Stone Disease

Download Full-text

SINGLE-NUCLEOTIDE POLYMORPHISMS OF CALCIUM-SENSING RECEPTOR ENCODING GENE ASSOCIATED WITH CALCIUM KIDNEY STONE DISEASE IN BABYLON PROVINCE

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2018.v11i2.22064 ◽

2018 ◽

Vol 11 (2) ◽

pp. 417 ◽

Cited By ~ 1

Author(s):

Zahraa Isam ◽

Rabab Omran ◽

Ammad Hassan Mahmood

Keyword(s):

Amino Acid ◽

Single Nucleotide Polymorphisms ◽

Kidney Stone ◽

Stone Disease ◽

Control Group ◽

Nucleotide Polymorphisms ◽

Calcium Sensing Receptor ◽

Single Nucleotide ◽

Kidney Stone Disease ◽

Calcium Sensing

Objective: The calcium-sensing receptor (CASR) is a G-protein-coupled receptor that is mainly expressed in the parathyroid and the kidneys where it regulates parathyroid hormone secretion and renal tubular calcium reabsorption. Inactivating and activating CASR gene due to mutations severally caused hypercalcemia or hypocalcemia disorders. The aim of the study was to investigate the risk factor of CASR rs1801725 (Ala986Ser) patients with renal disease.Method: The blood samples were collected from 100 patients and divided into two groups, each one containing 50 samples; chronic kidney disease and end-stage renal disease, who admitted Merjan Teaching Hospital in Babylon Province, Iraq, from February to July 2016. In addition, healthy persons as a control group (50 samples). Genotyping of CASR single-nucleotide polymorphisms (SNP) was performed using a polymerase chain reaction technique, followed by single-strand conformation polymorphism. Accordingly, these DNA polymorphisms were confirmed using DNA sequencing.Results: The conformational haplotypes of CASR, exon7 NCBI Primer3plus reference were obtained in three patterns, including two, three, and four bands, due to the presence SNPs within the studied region. These SNPs leads to change three amino acid residues of CASR, including amino acid substitutions were Ala 128→ Ser 128, Leu 155→Tye 155, and Leu 156→ Ser 156 that may affect or modified the tertiary structure of the receptor, subsequently the function like the affinity to calcium ion may be effected.Conclusion: These results suggest that the variants of CASR SNP, namely, rs1801725 might be involved in susceptibility to kidney stone disease.

Download Full-text

KIDNEY STONE DISEASE WITH SPECIAL REGARD TO DRUG-INDUCED KIDNEY STONES – A CONTEMPORARY SYNOPSIS

Wiadomości Lekarskie ◽

10.36740/wlek202009226 ◽

2020 ◽

Vol 73 (9) ◽

pp. 2031-2039

Author(s):

Łukasz Dobrek

Keyword(s):

Urinary Tract ◽

Kidney Stones ◽

Kidney Stone ◽

Stone Disease ◽

Urinary Stones ◽

Drug Induced ◽

Kidney Stone Disease ◽

Increased Risk ◽

Endogenous Compounds

Kidney stone disease (nephrolithiasis; urolithiasis) is a clinical entity with long-term course and recurrence, primarily affecting mature and ageing men, involving the formation and presence of urinary stones in the kidneys and urinary tract. The pathogenesis of this disorder is complex and still not fully understood. A rare, potentially modifiable, form of kidney stone disease takes the form of drug-induced urinary stones. The aim of the review was a brief description of the classification and pathophysiology of kidney stone disease, along with the short characteristics of drug-induced urinary stones. This type of stones is formed as a result of crystallisation in the kidneys and urinary tract of sparingly soluble drugs and their metabolites, or as a result of metabolic changes caused by drugs, predestinating the development of stones containing endogenous compounds. Conclusion: Therefore, during treatment with the use of drugs with high lithogenic potential, the safety of pharmacotherapy should be monitored in the context of its increased risk of developing urinary stones.

Download Full-text

The impact of metaphylaxis of kidney stone disease in the renal function at long term in active kidney stone formers patients

Urological Research ◽

10.1007/s00240-011-0407-5 ◽

2011 ◽

Vol 40 (3) ◽

pp. 225-229 ◽

Cited By ~ 4

Author(s):

Jose A. Meneses ◽

Fernando M. Lucas ◽

Fernando C. Assunção ◽

Junia P. P. Castro ◽

Rogério B. Monteiro

Keyword(s):

Renal Function ◽

Kidney Stone ◽

Stone Disease ◽

Kidney Stone Disease ◽

Stone Formers ◽

The Impact

Download Full-text

Association of CASR, CALCR, and ORAI1 Genes Polymorphisms With the Calcium Urolithiasis Development in Russian Population

Frontiers in Genetics ◽

10.3389/fgene.2021.621049 ◽

2021 ◽

Vol 12 ◽

Author(s):

Maria M. Litvinova ◽

Kamil Khafizov ◽

Vitaly I. Korchagin ◽

Anna S. Speranskaya ◽

Aliy Yu. Asanov ◽

...

Keyword(s):

Kidney Stone ◽

Calcium Metabolism ◽

Molecular Genetic ◽

Molecular Genetic Analysis ◽

Stone Disease ◽

Russian Population ◽

Control Group ◽

Multifactor Dimensionality Reduction Analysis ◽

Kidney Stone Disease ◽

Calcium Urolithiasis

Kidney stone disease is an urgent medical and social problem. Genetic factors play an important role in the disease development. This study aims to establish an association between polymorphisms in genes coding for proteins involved in calcium metabolism and the development of calcium urolithiasis in Russian population. In this case-control study, we investigated 50 patients with calcium urolithiasis (experimental group) and 50 persons lacking signs of kidney stone disease (control group). For molecular genetic analysis we used a previously developed gene panel consisting of 33 polymorphisms in 15 genes involved in calcium metabolism: VDR, CASR, CALCR, OPN, MGP, PLAU, AQP1, DGKH, SLC34A1, CLDN14, TRPV6, KLOTHO, ORAI1, ALPL, and RGS14. High-throughput target sequencing was utilized to study the loci of interest. Odds ratios and 95% confidence intervals were used to estimate the association between each SNP and risk of urolithiasis development. Multifactor dimensionality reduction analysis was also carried out to analyze the gene-gene interaction. We found statistically significant (unadjusted p-value < 0.05) associations between calcium urolithiasis and the polymorphisms in the following genes: CASR rs1042636 (OR = 3.18 for allele A), CALCR rs1801197 (OR = 6.84 for allele A), and ORAI1 rs6486795 (OR = 2.25 for allele C). The maximum OR was shown for AA genotypes in loci rs1042636 (CASR) and rs1801197 (CALCR) (OR = 4.71, OR = 11.8, respectively). After adjustment by Benjamini-Hochberg FDR we found only CALCR (rs1801197) was significantly associated with the risk of calcium urolithiasis development. There was no relationship between recurrent course of the disease and family history of urolithiasis in investigated patients. Thus we found a statistically significant association of polymorphism rs1801197 (gene CALCR) with calcium urolithiasis in Russian population.

Download Full-text

Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia

Hormone Molecular Biology and Clinical Investigation ◽

10.1515/hmbci-2015-0015 ◽

2015 ◽

Vol 23 (3) ◽

Cited By ~ 7

Author(s):

Abdulmaged M. Traish ◽

Karim Sultan Haider ◽

Gheorghe Doros ◽

Ahmad Haider

Keyword(s):

Erectile Dysfunction ◽

Benign Prostatic Hyperplasia ◽

Side Effects ◽

Adverse Effects ◽

Erectile Function ◽

Prostatic Hyperplasia ◽

Continuous Treatment ◽

Plasma Testosterone ◽

The Impact

Abstract5α-reductase inhibitors (5α-RIs) (finasteride and dutasteride) have been proven useful in treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). However, these inhibitors exert undesirable sexual side effects and, in some cases, these effects are persistent. There is considerable disagreement with regard to whether the adverse side effects resolve with continuous treatment.To investigate the long-term adverse effects of finasteride treatment in men with BPH on erectile function and to compare these adverse effects in men treated with the α1-adrenergic receptor blocker, tamsolusin.In this retrospective registry study, a cohort of 470 men aged between 47 and 68 years (mean 57.78±4.81) were treated with finasteride (5 mg/day). A second cohort of 230 men aged between 52 and 72 years (mean 62.62±4.65) were treated with tamsulosin (0.4 mg). All men were followed up for 45 months. At intervals of 3 months and at each visit, plasma testosterone (T) levels and the international index of erectile function (IIEF-EF) questionnaire scores were determined.Long-term treatment with finasteride therapy is associated with worsening of erectile dysfunction (ED) as shown by the significant decrease in the IIEF-EF scores in men treated with finasteride. No worsening of ED was observed in men treated with tamsulosin. The increase in ED due to finasteride did not resolve with continued treatment with finasteride. Most importantly, long-term finasteride therapy resulted in reduction in total T levels, contributing to a state of hypogonadism. On the contrary, no changes in T levels were noted in men treated with tamsolusin.Our findings suggest that in men with BPH, long-term finasteride therapy but not tamsulosin results in worsening of ED and reduces total T concentrations. Clinicians are urged to discuss the impact of 5α-RIs therapy on sexual function with their patients before commencing this therapy.

Download Full-text